want to know more?
+31 (0)20 303 1970

The SARS-CoV-2 coronavirus encodes a papain-like cysteine protease PLpro (NSP3) that cleaves the viral polyprotein, removes ubiquitin-like ISG15 protein modifications and (with lower activity) Lys48-linked polyubiquitin chains. As PLPro is essential for SARS-CoV-2 replication, it represents a promising target for the development of antiviral drugs. In light of this and to complement our well-known ubiquitin based reagents, we are expanding our portfolio of ISG15 based reagents.....(more)

 

 

Read More

The global epidemic of three coronaviruses has emerged in this century so far: SARS-CoV-1 in 2002, MERS-CoV in 2012 and SARS-CoV-2 in 2019. Current studies indicate that SARS-CoV-2 is similar to SARS-CoV-1. Although these three coronaviruses are identified as highly pathogenic for humans, there is no effective antiviral treatment. Therefore, current studies are focused on rapid development of vaccines and antiviral drugs to prevent and treat coronavirus infection....(more)

 

 

Read More

First of all, we wish all of our customers and partners well during this COVID-19 pandemic.
Below we have listed some recent publications in which UbiQ participated and that might be of interest to you....(more)

 

 

Read More

On the 19th of May 2020, our co-founder and dear friend Professor Dr. Huib Ovaa passed away from prostate cancer at the age of 46 years. In the past year, Huib has undergone a variety of treatments while continuing to do what he loved so much, being a scientist and mentor. We will miss him and always be grateful for his valuable contributions to our company and the ubiquitin field.
Farid El Oualid and Alfred Nijkerk
(more)

Read More

As we are near the end of this year, we would like to thank our worldwide scientific colleagues for their trust and collaborations. We are proud to be part of various exciting projects, and as such we have outlined below some important published insights which resulted from these collaborations...(more)

Read More

Conserved from yeast to human, the histone methyltransferase Dot1 methylates lysine 79 of histone H3 (H3K79) on the nucleosome core. This methylation affects gene expression and DNA damage response, and is enhanced by monoubiquitination of the C-terminus of histone H2B [1 - 4]. Given the promising clinical development of Dot1 inhibitors (e.g. for the treatment of acute leukemia in children [5]), it is important to elucidate the regulatory mechanisms of Dot1 [1 - 4].......(more)

 

Read More

A recent paper in Nature Communications describes a collaborative effort between scientists at UbiQ, Genentech, Boston Biochem (Bio-Techne) and Stanford University (1). Here a reactive-site-centric chemoproteomics protocol is presented which allows evaluating activity and probe reactivity of deubiquitinating enzymes (DUBs, also termed deubiquitylases)......(more)

 

Read More

Hereby we present UbiQ-121 as an activity-based probe for OTULIN, a deubiquitinating enzyme that is specific for Met1 linked ubiquitin chains and acts as a negative regulator of nuclear factor κB signaling and immune homeostasis. UbiQ-121 is based on Met1 linked diubiquitin in which G76 of the distal ubiquitin is replaced by an electrophilic dehydroalanine (Dha) residue. The catalytic cysteine residue of OTULIN reacts in a covalent manner with the Dha residue and as such UbiQ-121 captures OTULIN in its active conformation .....(more)

 

Read More

UbiQ secures 2.7 mioEUR EUROSTARS grant to tackle SUMOylation.

 

 

 

Read More

Ub photoLeu73 (UbiQ-154), a new and powerful crosslinkable Ub. UbiQ-154 is a new crosslinking reagent based on ubiquitin in which Leu73 is replaced by the photoreactive analog photoleucine.....(more)

 

Read More

Cell Chemical Biology paper: Proteasome Activation by Small Molecules;

The use of chemical probe Me4BodipyFL-Ahx3Leu3VS for identification of novel proteasome activity- modulating compounds.

Read More

UbiQ is now looking for an early career Researcher to join our Drug Discovery team.

(NB: Closing date was 17 April 2017, position has been filled successfully)

Read More

Mercachem and UbiQ join forces to tackle SUMOylation.

Read More

In honor of Prof. Yoshinori Ohsumi being awarded the Nobel prize in Medicine for his discoveries of mechanisms for autophagy, UbiQ has developed the activity-based probe His6-3C-MAP1LC3a-Dha (UbiQ-158). 

Read More

We here present UbiQ-141 (Mca-KKVAPYPME-Dap(Dnp)–NH2), which is a fluorogenic proteasome activity assay reagent based on the LF-2 peptide sequence. The reagent can be used to study activating factors of proteasome activity.*

Read More

Our publication highlights newsletter serves to highlight some of the recent reported work in the Ubiquitin Proteasome Field.

Read More

structural biology of UPS enzymes

with activity-based probes

Read More

We proudly present our new and revolutionary activity-based probes for the E1-E2-E3 enzyme cascade. Our Triple E probes represent the first tools that allow the monitoring of full E1-E2-E3 cascade activity.

Read More

New DUB probes allow you to study DUBs that use S2 ubiquitin pocket binding to modulate DUB activity.

Read More

Recently we introduced a new type of quenched ubiquitin rhodamine110 assay reagent, Ub-Rh110MP (UbiQ-126). In this newsletter we present some performance data.

Read More

To identify DUB inhibition, a competitive DUB activity profiling was performed using UbiQ’s activity based DUB probes. 

Read More

Here we would like to make a plea for in-gel fluorescent scanning by using fluorescently labeled probes. A method with many advantages.

Read More

UbiQ is introducing a new type of ubiquitin-rhodamine110 DUB assay reagent that doubles the fluorescence intensity.

Read More

Tools to support a new frontier of ubiquitin signalling research.

UbiQ has developed new tools, on the interface of ubiquitylation and phosphorylation signalling.

Read More

UbiQ has developed PINK1/Parkin related phosphorylated ubiquitins in cooperation with Ubiquigent and MRC Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee.

Read More

UbiQ and Ubiquigent have entered into a collaboration to commercialise novel reagents addressing a new frontier of integrated ubiquitylation and phosphorylation research central to Parkinson's disease.

Read More

UbiQ and Neuroscience Campus Amsterdam join forces to develop treatments for Parkinson’s disease and other neurodegenerative illnesses.

Read More

Publication on active-site directed probes in JACS

On terminal alkynes that can react with active-site cysteine nucleophiles in proteases. Reggy Ekkebus , Sander Izaak van Kasteren , Yogesh Kulath... 

Read More

UbiQ-PEP™: custom ubiquitinated peptide synthesis

Read More